Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies By admin / 10/27/2016
Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: Integrated Analysis of TGR-1202 monotherapy and combined with ublituximab By admin / 06/01/2016
Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. By admin / 12/08/2015
Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma. By admin / 12/09/2014
Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial. By admin / 06/13/2014
Ublituximab (TG-1101), A Novel Anti-CD20 Monoclonal Antibody for Rituximab Relapsed/Refractory B-Cell Malignancies. By admin / 06/13/2014
A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab. By admin / 05/30/2014
The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells. By admin / 12/10/2013
Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies. By admin / 06/14/2013
A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients. By admin / 06/02/2013
